A team of scientists from different universities across Europe has developed an innovative method of delivering vaccines directly to the white blood cells in order to boost the immune system against life-threatening diseases. They have devised a tough microcapsule using synthetic spider silk that can deliver vaccines directly to T-cells.
With sufficient evidence, it was proved that community water fluoridation would provide proper dental health benefits for children and adolescents in the U.S. It is this advised to start consuming fluoridated drinking water as early as possible, anywhere between the ages of 2-8 years.
Precision medicine is an emerging approach for disease treatment where genes, the environment and lifestyle of each person is taken into account.
This rural telehealth consultation program named Specialty Care Access Network-Extension for Community Healthcare Outcomes (SCAN-ECHO) was launched by the Department of Veterans Affairs in New Mexico in 2012. To begin with, this program was used for chronic liver disease. This consultation connected rural care teams to specialty clinics, where the patients can be treated in a better way.
Biopharma Sarepta Therapeutics and Brammer Bio enter into a long-term strategic partnership to design and develop new manufacturing facilities at CDMO’s plant in Massachusetts. The new partnership is for the development of the production of its microdystrophin, Duchenne Muscular Dystrophy (DMD) therapy and future gene therapies.
Calliditas Therapeutics is planning to raise $75 million through an Initial Public Offering in Sweden. The new investment capital will help Calliditas fund a phase 3 clinical trial of autoimmune kidney disease anticipated to start later this year.
DyAnsys’ Drug Relief, a wearable that is worn around the patient’s ear, is a neurostimulation therapy that helps to relieve the symptoms of opioid withdrawal such as depression, anxiety and cravings.
In an innovative push to help biotech start-ups in Britain become independent medium-sized enterprises, the U.K. set up a £2.5 billion patient capital program.
On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkins lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.
When satellite cells don’t function properly, deterioration of muscles occurs, leading to muscle weakness and fibrosis.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.